Loading...
Esperion Q1 2025 Earnings Report
Esperion reported its financial results for the first quarter ended March 31, 2025, with total revenue of $65.0 million and a net loss of $40.5 million.
Key Takeaways
Esperion reported a total revenue of $65.0 million for Q1 2025, a 53% decrease year-over-year, primarily due to a one-time milestone received in Q1 2024. Excluding this milestone, total revenue grew 63%. The company achieved a net loss of $40.5 million and a basic net loss per share of $0.21.
Total revenue for Q1 2025 was $65.0 million, a 53% decrease year-over-year, but a 63% increase excluding a one-time milestone from Q1 2024.
U.S. net product revenue grew 41% year-over-year to $34.9 million.
The company surpassed one million retail prescription equivalents for its bempedoic acid products in the U.S.
Bempedoic acid earned Level 1a recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes.
Esperion
Esperion
Esperion Revenue by Segment
Revenue by Segment
U.S. Net Product Revenue
CapyFin.comCollaboration Revenue
CapyFin.com Forward Guidance
Esperion expects full year 2025 operating expenses to be in the range of $215 million to $235 million, including approximately $15 million in non-cash expenses related to stock compensation.
Positive Outlook
- The Company's partner in Japan, Otsuka Pharmaceutical Co., Ltd. is on track for expected approval and National Health Insurance pricing in the second half of 2025.
- Esperion's European partner Daiichi Sankyo Europe (DSE) continues to show strong revenue growth and market penetration.
- DSE received approval of NILEMDO for expanded cardiovascular risk reduction in Switzerland in Q1 2025.
- Neopharm Israel filed a New Drug Application for marketing approval of NEXLETOL and NEXLIZET in Q1 2025.
- The Company's previously filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET are on track for review with an expected market approval in the fourth quarter of 2025.